Form 4: Collegium Pharma Director Trades RSUs and Options

John Gordon Freund, a Director at Collegium Pharmaceutical, Inc., reported transactions involving restricted stock units (RSUs) and stock options.

Summary

• Director John Gordon Freund acquired 8,741 restricted stock units (RSUs) on May 14, 2026, with a reported value of $0. This transaction is explained as a grant of RSUs that vest on May 14, 2027, or the date of the 2027 Annual Meeting of Shareholders, subject to continued service.
• On May 15, 2026, Freund acquired 8,700 shares of common stock through the exercise of a stock option at a price of $16.49 per share, increasing his direct beneficial ownership to 88,099 shares.
• Also on May 15, 2026, Freund disposed of 4,127 shares of common stock at a price of $34.54 per share, reducing his direct beneficial ownership to 83,972 shares.
• Indirect beneficial ownership is noted through John Freund Family Partnership IV, L.P. (23,129 shares) and Skyline Venture Management V, LLC (8,625 shares).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine insider transactions related to equity compensation and personal investment adjustments, without significant positive or negative strategic implications.

Positives

• Acquisition of 8,741 RSUs indicates a long-term incentive aligned with director service.
• Exercise of a vested stock option and subsequent acquisition of shares suggests potential for capital appreciation.
• The disposal of shares at a higher price ($34.54) than the option exercise price ($16.49) indicates a profitable transaction for the director.

Negatives

• Disposal of 4,127 shares could be interpreted as a partial liquidation of holdings by a director.

Future Outlook

The RSUs granted are subject to vesting conditions tied to continued service and future corporate events, indicating a long-term incentive structure for the director.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The reported transactions by a director of Collegium Pharmaceutical, Inc. (COLL) are typical for executives and board members managing their equity compensation and personal investment strategies.

Stakeholder Impact

• Shareholders: The transactions reflect a director managing their equity compensation and personal holdings, which is standard. The sale of shares at a profit is a normal outcome of option exercises.

Next Steps

• RSUs will vest on May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders, subject to continued service.
• RSUs will be settled on the vesting date or earlier upon election, based on service end, death, disability, or change in control.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Options, Restricted Stock Units, Director Transactions, Beneficial Ownership, Collegium Pharmaceutical, COLL